Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017:2017:3510984.
doi: 10.1155/2017/3510984. Epub 2017 Feb 28.

A Novel Panel of Serum Biomarkers for MPM Diagnosis

A Bonotti  1 , R Foddis  2 , S Landi  3 , O Melaiu  3 , C De Santi  3 , L Giusti  4 , E Donadio  4 , F Ciregia  4 , M R Mazzoni  4 , A Lucacchini  4 , M Bovenzi  5 , M Comar  5 , E Pantani  1 , A Pistelli  1 , A Cristaudo  6
Affiliations

A Novel Panel of Serum Biomarkers for MPM Diagnosis

A Bonotti et al. Dis Markers. 2017.

Abstract

Exposure to asbestos is the main cause of malignant pleural mesothelioma (MPM), a highly aggressive cancer of the pleura. Since the only tools for early detection are based on radiological tests, some authors focused on serum markers (i.e., mesothelin). The aim of this study was the evaluation of new serum biomarkers to be used individually or in combination, in order to improve the outcome of patients whose disease would be diagnosed at an earlier stage. Serum and plasma were available from 43 subjects previously exposed to asbestos and 27 MPM patients, all being epithelioid type. All the new markers found differentially expressed in MPM and healthy subjects, by proteomic and genomic approaches, have been validated in the serum by the use of specific ELISA. The combined approach, using tools of genomics and proteomics, is found to be highly innovative for this type of disease and led to the identification of new serum markers in the diagnosis of MPM. These results, if confirmed in a larger series, may have a strong impact in this area, because early detection of this cancer in people at high risk could significantly improve the course of the disease and the clinical approach to an individualized therapy.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Figure 1
Figure 1
Biomarkers combinations were graphically shown.
See this image and copyright information in PMC

References

    1. Peto J., Decarli A., La Vecchia C., Levi F., Negri E. The European mesothelioma epidemic. British Journal of Cancer. 1999;79(3-4):666–672. doi: 10.1038/sj.bjc.6690105. - DOI - PMC - PubMed
    1. Rusch V. W., Giroux D., Kennedy C., et al. Initial analysis of the international association for the study of lung cancer mesothelioma database. Journal of Thoracic Oncology. 2012;7(11):1631–1639. doi: 10.1097/JTO.0b013e31826915f1. - DOI - PubMed
    1. Zellos L., Christiani D. C. Epidemiology, biologic behavior, and natural history of mesothelioma. Thoracic Surgery Clinics. 2004;14(4):469–477. doi: 10.1016/j.thorsurg.2004.06.011. - DOI - PubMed
    1. Robinson B. W. S., Creaney J., Lake R., et al. Soluble mesothelin-related protein—a blood test for mesothelioma. Lung Cancer. 2005;49(1):S109–S111. doi: 10.1016/j.lungcan.2005.03.020. - DOI - PubMed
    1. Hollevoet K., Reitsma J. B., Creaney J., et al. Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis. Journal of Clinical Oncology. 2012;30(13):1541–1549. doi: 10.1200/jco.2011.39.6671. - DOI - PMC - PubMed

LinkOut - more resources